Schizophrenia is increasingly recognized as a neurodevelopmental disease with an additional degenerative component, comprising cognitive decline and loss of cortical gray matter. We hypothesized that a neuroprotective/neurotrophic add-on strategy, recombinant human erythropoietin (rhEPO) in addition to stable antipsychotic medication, may be able to improve cognitive function even in chronic schizophrenic patients. Therefore, we designed a doubleblind, placebo-controlled, randomized, multicenter, proof-of-principle (phase II) study. This study had a total duration of 2 years and an individual duration of 12 weeks with an additional safety visit at 16 weeks. Chronic schizophrenic men (N = 39) with defined cognitive deficit (X1 s.d. below normal in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)), stable medication and disease state, were treated for 3 months with a weekly short (15 min) intravenous infusion of 40 000 IU rhEPO (N = 20) or placebo (N = 19). Main outcome measure was schizophrenia-relevant cognitive function at week 12. The neuropsychological test set (RBANS subtests delayed memory, language-semantic fluency, attention and Wisconsin Card Sorting Test (WCST-64) -perseverative errors) was applied over 2 days at baseline, 2 weeks, 4 weeks and 12 weeks of study participation. Both placebo and rhEPO patients improved in all evaluated categories. Patients receiving rhEPO showed a significant improvement over placebo patients in schizophrenia-related cognitive performance (RBANS subtests, WCST-64), but no effects on psychopathology or social functioning. Also, a significant decline in serum levels of S100B, a glial damage marker, occurred upon rhEPO. The fact that rhEPO is the first compound to exert a selective and lasting beneficial effect on cognition should encourage new treatment strategies for schizophrenia.
Introduction
Schizophrenia is a common and devastating disease, affecting approximately 1% of the population across cultures, mainly young people, with two-thirds of them displaying severe losses of their previously acquired cognitive capacity. [1] [2] [3] [4] Among those, many fulfill the deterioration criteria of Kraepelin's dementia praecox. 5 These facts already justify the use of the term degeneration in schizophrenia. Further neurodegenerative aspects of the disease, however, are still a matter of dispute among scientists while there is overall agreement on neurodevelopmental alterations providing the ground for schizophrenia. 6 The disability of schizophrenic patients is a composite of persistent positive symptoms, cognitive
The increasing evidence of neurodegenerative mechanisms acting in schizophrenia, particularly that derived from imaging data demonstrating progressive loss of cortical gray matter in this condition, [18] [19] [20] have led to a virtual renaissance of Kraepelin's dementia praecox considerations, 5 and have stimulated novel concepts of the disease, 7, [21] [22] [23] [24] [25] including therapeutic neuroprotection. 26 Based on previous observations by ourselves and others, erythropoietin (EPO) appears to be a promising candidate for neuroprotection in schizophrenia. [26] [27] [28] EPO can be expected to address some of the pathophysiological mechanisms involved in the manifestation of schizophrenic psychosis. In particular, it exerts neurotrophic and synaptogenic activity. 27, [29] [30] [31] [32] Encouraging results on its neuroprotective/neurotrophic power in man have been obtained from our recent treatment trial in stroke patients. 28 In previous work, we have shown by using nuclear imaging technology in man that peripherally applied recombinant human EPO (rhEPO) penetrates into the brain. Moreover, we demonstrated that rhEPO is enriched intracranially, and notably more in schizophrenic patients than in healthy controls. In line with reactive EPO receptor expression in the brain upon metabolic distress, 33 we found EPO receptors densely expressed in the hippocampus and cortex of schizophrenic subjects, but not of healthy individuals. 26 Most importantly, we demonstrated in a murine lesion model of progressive neurodegeneration, resembling features of schizophrenia, that long-term behavioral alterations as well as brain atrophy could be prevented by rhEPO. 34 These observations, together with the known safety of rhEPO, let us initiate the present proof-of-principle trial exploring whether a neuroprotective/neurotrophic add-on strategy (rhEPO in addition to stable antipsychotic medication) that targets cognition may be a promising novel approach to treatment of schizophrenia.
Although first episode schizophrenic patients with their progressing cognitive deterioration would certainly have been the population of choice for the present double-blind, placebo-controlled, randomized, multicenter trial, we took the risk to focus on chronically ill, cognitively impaired schizophrenic patients without clear signs of ongoing disease progression. 35 We did this due to ethical considerations (long-term compliance, informed consent, legal situation in a first proof-of-principle trial) but, most importantly, under the assumption that any brain has potential to recover, with processes of degeneration and regeneration constantly running in parallel. Here we show that a hematopoietic growth factor, rhEPO, with its putative effects on neuroplasticity, can improve cognitive functioning in schizophrenia.
Materials and methods

Patients and procedures
The protocol for the present phase II multicenter trial ('EPO-schizophrenia study') was approved by the ethical committee of the Georg-August-University of Gö ttingen (master committee) as well as by the respective ethical committees of all other participating centers. Written informed consent by patients or their authorized legal representatives was required. Between April 2003 and March 2005, 39 patients, out of 172 screened for participation, have completed the trial ( Figure 1 ). Of the 43 patients who had originally been included in the study, two changed their minds immediately after having signed in, before they received any study medication (both Gö ttingen), and two patients dropped out during the course of the trial (Marburg, Gö ttingen), both belonging to the placebo group. Both of these late drop-outs skipped their antipsychotic medication on their own, developed an acute episode and discontinued the trial. All other patients were highly compliant and concluded the study as planned.
The trial was set up as a double-blind, placebocontrolled, randomized, multicenter trial. Of the 39 study completers, 17 were from Gö ttingen, 14 from Kiel, four from Homburg, three from Cologne and one from Marburg. Total duration of the study was 2 years (from April 2003 to March 2005), individual duration 12 weeks of weekly treatment with an additional safety visit at 16 weeks. The intervention consisted of weekly administration of rhEPO (40 000 IU of EPObeta, Roche, Grenzach, Whylen, Germany) or placebo as a short (15 min) intravenous infusion.
After careful baseline examination and confirmation of inclusion/exclusion criteria, patients were asked to return weekly for application of the study drug, documentation of any other medication, monitoring of adverse events and safety, including measurement of blood pressure and routine laboratory testing. Blood letting (350-450 ml) was performed if the hematocrit exceeded 50% on two consecutive weeks.
Study end points were cognitive function, tested over 2 days at baseline, and at 2, 4 and 12 weeks of study participation. The 'cognitive test package' applied included the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; ABAB design), 36 the Wisconsin Card Sorting Test (WCST-64) 37 and a test of premorbid intelligence 41 the Disability Assessment Schedule (DAS-M), 42 both performed at baseline, 2 weeks, 4 weeks and 12 weeks. As motor tests, the subtests Tapping and Dotting from the MacQuarrie Test for Mechanical Ability 43 were performed at baseline, 2 weeks, 4 weeks and 12 weeks.
For morphological assessment, magnetic resonance imaging (MRI) was conducted at baseline and after 3 months. High-resolution three-dimensional (3D) T1-weighted gradient echo sequences (spoiled 3D FLASH, 1 mm isotropic) were applied. Volumetrical analysis was performed using FSL 3.2 Software (FMRIB Analysis Group, Oxford, UK). Data sets of baseline and follow-up examinations were co-registered and analyzed using the SIENA tool (Structural Image Evaluation Using Normalisation of Atrophy) of FSL. For basic primary analysis, whole-brain volume was assessed.
In order to provide optimal logistics, for example with respect to timely delivery of study medication to the centers, and to guarantee the highest possible inter-rater agreement, a comprehensive 2-day training workshop was organized for all participating centers and their physicians/psychologists. Figure 2 gives an overview of visits and tests performed during the trial.
Inclusion and exclusion criteria
For homogeneity reasons, only male patients were included, age 25-50 years. They had to meet criteria for Diagnostic and Statistical Manual of Mental Disorders (DSM) IV diagnosis of schizophrenia. At least 10 years should have elapsed since hospitalization due to their first acute episode. Patients should not have had any acute episode throughout the previous 6 months, and negative symptoms had to have stably existed throughout the previous year. On presentation for study participation, PANSS Negative Syndrome Scale was required to be X20 and PANSS General Psychopathology Scale X48. Only patients with outlasting cognitive deficits affecting working memory, executive functions and attention were included. Their cognitive performance had to be at least 1 s.d. below normal in the RBANS. Exclusion criteria were acute psychosis as characterized by a change in state, requiring an intervention (additionally, requirement of a PANSS Positive Syndrome Scale p28 should restrict severity of positive symptoms in the patient population), organic psychosis, other severe diseases, use of illicit drugs, alcohol dependence, high thrombembolic risk factors, myeloproliferative disorders or hematocrit > 50%. Study-related exclusion criteria would have been (1) interruption of study medication for more than 2 weeks or (2) missing of study medication more than two times (20%). Safety-related exclusion criteria would have been a diastolic blood pressure X100 mm Hg twice daily on 3 consecutive days.
All medication had to be documented. Prerequisite for inclusion was stable medication with psychoactive drugs at least over the last 2-3 months. Regarding antipsychotic treatment, both typical and atypical antipsychotics were allowed. Patients with stable benzodiazepine medication were not excluded. Additional psychotropic medication, including newly prescribed benzodiazepines, had to be avoided. For critical situations, requiring short-term additional medication (two cases), neuropsychological testing had to be postponed until at least 8 days after the last administration of this medication (e.g. benzodiazepines).
For blinding, the pharmacist prepared and numbered identical vials containing either saline (0.9% NaCl) or rhEPO reconstituted in saline. Upon enrolment, the vials were randomly assigned to patients with the contents of vials known only by the pharmacist. For randomization, a block design with approximately equal numbers of subjects randomized to each condition according to site was applied. To guarantee double-blinding as much as possible, none of the clinicians performing neuropsychological or psychopathological analysis had access to any of the laboratory data obtained (red blood cell counts, including reticulocytes, parameters of iron metabolism) during the study. Serum-EPO levels were analyzed only after unblinding of the study.
Assays for EPO, S100B, interleukin-6 and hepcidin prohormone in serum Concentrations of EPO were measured in serum, using a commercially available ELISA kit (R&D Systems, Wiesbaden, Germany) according to the manufacturer's protocol. Commercial assays were also used for determining S100B (DiaSorin, Dietzenbach, Germany), interleukin-6 (IL-6, R&D Systems, Wiesbaden, Germany) and hepcidin prohormone (DRG Instruments GmbH, Marburg, Germany). Serum samples were not analyzed before unblinding of the study. Sample analysis of EPO and placebo patients was performed blinded and in random order, using adequate inter-and intra-assay controls. Inter-and intra-assay coefficients of variation did not exceed 8% in any of the assays.
Routine laboratory analyses
Determination of routine laboratory data was performed in the Department of Clinical Chemistry of the Georg-August-University Gö ttingen, according to standard procedures.
Statistical analysis
Primary outcome measure in this proof-of-principle study was a neuropsychological test set covering functions that were (1) found to be most severely impaired in our patient population at baseline and (2) known to be predominantly affected in chronic schizophrenia: RBANS subtests delayed memory, language-semantic fluency and attention, as well as WCST-64 -perseverative errors. [44] [45] [46] [47] For analysis, raw data were used throughout the paper. To determine the composite score, they were z-transformed. For illustration of the core findings in Figure 3 , ztransformation was followed by transformation to regular intelligence quotient (IQ) standard (scale) values, and expression of the data as percent individual baseline. The exploratory use of normative instead of raw data yielded comparable results and significance levels. 
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Although the present trial -including our cognitive test set -has been designed well before the NIMH initiative on Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS), the test set covers six of the seven domains of the MATRICS consensus cognitive battery for use in clinical trials: speed of processing, attention/vigilance, working memory, verbal learning and memory, visual learning and memory, reasoning and problem solving. 48 Only the MATRICS domain 'social cognition' is not specifically contained in our test set. Among the cognitive tests performed but not included in the test set, mainly due to their lower sensitivity in schizophrenic patients, 14, 47 were RBANS subtests visuospatial function, language-picture naming and immediate memory. Secondary end points were timedependent changes in psychopathology scores, motor function (tapping and dotting), blood parameters and MRI volumetrical data.
Several considerations guided our statistical analysis plan. First, repeated-measures analysis of covariance (repeated-measures ANCOVA) was performed, with the primary outcome measure (schizophreniarelated cognitive test set) serving as the dependent variable, and treatment as the independent variable, and with age (a major determinant of neuropsychological functioning) as a covariate in the analysis. The study protocol requested comparison of cognitive performance at baseline to week 12 of treatment. In addition, the in-between time points were evaluated in a descriptive manner to estimate the course of changes over time. Addition of other covariates such as MWT-B (a measure of premorbid intelligence) or type and amount of medication did not change the results of the analysis (see Results section). In order to account for the tendency of different baseline performance in cognitive testing found upon unblinding of the study between the two groups, the same analysis as described above was performed, with the exception that cognitive outcome measures were expressed as percent of the individual baseline level. This way of analysis further supported the results (see Results section). To employ yet another confirmatory procedure, the main outcome measures of the present study were also analyzed using a linear mixed model approach modeling the time trends in cognitive function from baseline (week 1) to weeks 2, 4 and 12. The treatment group was a categorical variable, whereas age was a quantitative covariate. Additional statistical testing included t-tests, w 2 -tests and Pearson's correlations. For all statistical analyses, the program SPSS for Windows, release 12, was used. 49, 50 All tests were two-tailed and, due to the exploratory character of the study, P-values were not adjusted for the number of tests that were performed. Thus, results should be considered of being preliminary. Mean (M) and s.d. are given to describe results in the text and tables, whereas in the figures M and s.e.m. are used.
Results
Of the patients completing the study (N = 39), most were included by the centers in Göttingen (N = 17) and Kiel (N = 14), and fewer patients by Homburg (N = 4), Cologne (N = 3) and Marburg (N = 1). Despite this unequal distribution of patients among centers, there was no indication of a center effect with respect to study results (see below).
Of 172 patients screened for participation in the study, only 43 fulfilled the enrolment criteria ( Figure 1 ). The most common reasons for exclusion were duration of disease less than 10 years, last acute episode less than 6 months ago, unstable medication, unwillingness to participate in a trial and PANSS scoring outside the requested limits.
No unexpected side effects, no adverse events and no complaints of the participating patients were identified throughout the study. Also, no changes in blood pressure were observed over time. A total of eight patients reached the criteria for blood letting (hematocrit X50 on two consecutive measurements): five patients had to be bled (350-450 ml) once, one patient twice, one patient three times and one patient five times. All bleedings were well tolerated.
Baseline characteristics of patients completing the study are presented in Table 1 . EPO and placebo group turned out to match well with respect to ), additional use of anticholinergic drugs, benzodiazepines or smoking habits (Table 2) .
Psychopathological data are presented in Table 3 . Upon inclusion, groups did not differ significantly with respect to PANSS scales, subjective well-being or DAS-M. PANSS negative and general psychopathology scales improved over time in both treatment groups, but did not show an interaction effect between group and time ( Table 3) .
The composite score of the set of schizophreniarelated cognitive tests (RBANS subtests delayed memory, language-semantic fluency, attention and (Figure 3 ). Repeatedmeasures ANCOVA using this composite score as the dependent variable and treatment as the independent variable, together with age as covariate, revealed a significantly better outcome of EPO as compared to placebo-treated patients. This result was obtained both by using raw data (P = 0.022, d.f. = 1, 35) and by calculating cognitive improvement based on the individual baseline level (P = 0.010, d.f. = 1, 35) ( Figure 3 ). In addition, we analyzed these data using a linear mixed model. 52 This alternative approach to Cognitive tests other than those selected as 'schizophrenia test set', and motor tests did not differ between groups upon inclusion or during follow-up (Table 4) . Also, single test analysis over time (in contrast to the composite score) did not yield significant differences between groups. In both groups, however, data improved over the study period, in particular initially, consistent with a drug-independent trial effect ( Table 4) .
Supporting our prospective statistical analysis plan that included age as covariate, our results confirm an influence of age on both cognitive function at baseline as well as on the increase of cognitive function from baseline to week 12. This influence of age, however, does not diminish the effect of EPO on cognitive outcome. In fact, when using raw data in the present ANCOVA, age does not show a significant main effect (P = 0.195), but it has a significant time Â age effect (P = 0.041). When calculating cognitive improvement based on the individual baseline level, age shows both a significant main effect (P = 0.008) and a significant interaction effect (P = 0.008).
Volumetrical analysis of whole-brain MRI data did not reveal significant differences between groups nor changes following treatment (total volume upon inclusion 1549.97108.8 ml versus 1474.67154.4 ml and after 12 weeks of treatment 1547.97106.0 ml versus 1468.37153.0 ml in EPO (n = 16) versus placebo (n = 12) patients, respectively).
Routine laboratory data over the course of the trial are presented in Table 5 , with significant differences between the groups marked in gray. Remarkable differences over time occurred, particularly with erythrocytes, reticulocytes, hemoglobin, hematocrit, mean corpuscular hemoglobin, transferrin and ferritin.
EPO levels did not differ among groups upon inclusion and remained in the same range over the whole study period, independent of treatment ( Table  6 ). Hepcidin prohormone, a recently discovered hepatic peptide that regulates intestinal iron absorption, 53, 54 was found unaffected by the high-dose EPO treatment as was the inflammatory cytokine IL-6, which had previously been found to be elevated in schizophrenia 55 (Table 6 ). Both hepcidin and IL-6 did not differ significantly between groups and were always within the normal range (according to the manufacturers).
In contrast, serum levels of the glial damage marker S100B, starting out from almost identical baseline concentrations in both groups (that did not differ from age-matched healthy men; N = 27), dissociated remarkably upon treatment, with the EPO group showing a significant decrease at week 12 (P = 0.025, d.f. = 1, 27) (Figure 4) . Repeated-measures ANCOVA, using S100B as the dependent variable, treatment as the independent variable and age as a covariate, did not identify further covariates of significant influence on this result (premorbid intelligence (MWT-B), duration of disease, baseline cognitive performance, PANSS negative or general psychopathology scores, chlorpromazine equivalents, hematologic parameters including blood letting, creatinine, body weight or height).
As already described above, the only covariate identified to be of significant influence on cognitive outcome was age. Specifically, there was no additional effect of S100B at week 12 or upon inclusion, medication, duration of disease, premorbid intelligence (MWT-B), baseline PANSS negative, positive or general psychopathology scores. Careful and comprehensive analysis of hematologic parameters, as altered by continuous high-dose rhEPO treatment, including delta values, with respect to a potential influence on cognitive outcome did not show significant effects.
When data obtained in Göttingen (nine EPO, eight placebo patients), in Kiel (seven EPO, seven placebo patients) and in the remaining three centers (four EPO, four placebo patients) were analyzed separately, they all resulted in the same pattern, with the EPO group superior to the placebo group. This finding excluded a major center bias explaining the result. Owing to the small number of patients in these separate analyses, however, this statistical maneuver did not yield significant differences anymore.
Discussion
In the present study, we show that a neuroprotective/ neurotrophic add-on strategy in a group of chronically ill schizophrenic men with defined cognitive deficit can lead to improvement of cognition. Weekly intravenous application of high-dose rhEPO over 12 weeks apparently induced a stepwise amelioration in a set of cognitive functions known to be most severely affected in schizophrenia. Additionally, EPO treatment resulted in a significant decrease in serum levels of the glial damage marker S100B. In contrast, rhEPO add-on treatment was unable to affect psychopathology ratings, measures of social functioning or brain volume during the 3 months of observation. In fact, all patients, placebo as well as EPO treated, improved during the study with respect to negative symptoms and general psychopathology.
Interestingly, the placebo group also showed cognitive improvement over the whole study period. This study-related, EPO-independent, effect on cognition goes hand in hand with the EPO-independent effects on negative symptoms and general psychopathology, and may to some degree be explained by the positive change in the monotonous life of these chronically ill patients through additional regular therapeutic and caring social interactions. Common factors like social training and increased structure, motivation and expectancy, recognition and importance, and boosting self-confidence may play a role. 56 Table 4 Cognitive raw data immediately before the first EPO/placebo infusion (week 1) and at three time points during treatment (N = 19-20, due to missing data at baseline of only one particular patient. For repeated-measures ANCOVA, this one patient has been excluded from the analysis resulting in N = 19 patients per group -compare Figure 3 
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Despite using an ABAB design of the two versions of the RBANS, a battery characterized by repeatability, 36 a neuropsychological training effect adding to the observed improvement in the placebo group cannot be entirely ruled out. In any case, the EPO group by far exceeds the placebo group with respect to cognitive outcome.
EPO was able to improve cognition without affecting any of the other schizophrenia typical symptoms. This distinct separation of effects by the drug might (1) point against a secondary beneficial effect on cognitive performance, for example, via reduction of negative symptoms and (2) allow for further conclusions with respect to disease-specific pathophysiological mechanisms.
Despite some recent literature describing beneficial effects of various antipsychotics on cognitive functioning, none of these studies has provided convincing evidence of cognitive improvement unrelated to recovery from acute episodes of the disease. [14] [15] [16] 57, 58 Also, in these studies, different antipsychotics have been tested against each other. 57, 58 In contrast, EPO has been able as an add-on treatment, on top of a stable antipsychotic medication regime, to specifically target cognition in a group of chronic schizophrenic patients with clearly defined, persistent cognitive decline. Even though the principal question Figure 4 Repeated-measures ANCOVA: effect of EPO versus placebo treatment on S100B serum levels in male chronic schizophrenic patients. S100B levels were measured in serum samples of 15 patients per treatment group. Covariate: age. As healthy controls, 27 age-matched men, serving as blood donors for the blood bank, were employed. M7s.e.m. presented. We interpret the effect of EPO to be of regenerative nature rather than to be due to a temporary cognitive enhancement, for two reasons: (1) the pattern of a steady increase in cognitive performance over time and (2) the fact that EPO serum levels returned back to normal each week before the next application of EPO. The improvement in cognition therefore occurred in the absence of an accumulation of compound.
Regarding the mechanism of action of EPO on cognition in schizophrenia, the observed gradual pattern of improvement may point to a morphological rather than a purely functional and short-lived effect. Not surprising, however, we have not been able to detect any changes in whole-brain volume as early as after 3 months of EPO treatment since measurable results on brain dimensions might not occur before 6 months. 59 Nevertheless, it was of importance, in light of planning future studies, to perform MRI before and after this first neuroprotective proof-of-concept trial in schizophrenia. Interestingly, EPO has been shown to influence synaptic/dendritic density 31 and function (synaptic transmission). 32 Thinking along these lines, improvement in cognition and in learning processes has been closely related to activation of MAP kinases. 60 These second messengers, in turn, are known to be stimulated by EPO in neurons. 27, [61] [62] [63] Another novel finding was the effect of EPO treatment on serum levels of the glial damage marker, S100B. Both groups, EPO and placebo, started out from identical baseline levels, not different from healthy controls. Although our healthy control levels are comparable to those reported by others, 64 the finding of normal values in schizophrenic patients is in some contrast to reports on elevated serum concentrations in this condition. 64, 65 In most previous publications, however, only patients within or shortly after an acute episode were investigated, whereas our inclusion criteria required the last episode dating back to more than 6 months. Surprisingly, despite normal S100B baseline levels, schizophrenic patients respond to rhEPO with a further decrease. Assuming that S100B is brain-derived, this phenomenon may have essentially two explanations: (1) EPO 'seals' the blood-brain barrier and prevents S100B from crossing into the circulation; (2) EPO reduces intracerebral S100B production. While there is evidence of an effect of EPO on blood-brain barrier function, 26, 66, 67 an interference of EPO with S100B production/release has not been reported yet. (In a series of preliminary experiments, we did not find any evidence of a suppressive effect of EPO on S100B release from human astrocytoma (U373) cells or an effect of EPO on cellular S100B content -data not shown.) In line with either one of these two interpretations, however, rhEPO was able to reduce elevated S100B levels in our previous stroke trial. 28 Nevertheless, it cannot be entirely excluded at this point that S100B in our schizophrenic patients is derived from other S100B producing tissues, for example, muscle or gut, 68 and that EPO interferes with their production, release or elimination of S100B. Interestingly, mutant mice, devoid of S100B, show improved memory function and enhanced long-term potentiation in hippocampal slices. 69 EPO was found to be safe in our hands in this particular setting. Patients were followed closely from week to week, and bloodlettings were performed wherever necessary and were well tolerated. No adverse events, in particular no thrombembolic complications or effects on blood pressure, were reported or observed. Nevertheless, recently developed non-erythropoietic EPO analogs like carbamylated EPO (CEPO) might be the compounds of choice to exploit neuroprotective effects of EPO without having to deal with its hematopoietic properties. 70 Despite the fact that both the group of patients and the effect on cognition were rather small, we hope that the present work will encourage new treatment strategies in schizophrenia. In this regard, our study has stimulated a number of additional questions and challenges: we cannot be sure whether dose and frequency of rhEPO application is already optimized. Moreover, future studies should also extend to first episode or even prodromal patient groups. They will have to last longer than 12 weeks and should include regular cognitive training, physical exercise and enhanced social exposure. We hypothesize that EPO will be most beneficial in a situation of major functional challenge. Rather than treating healthy sportsmen to ever-increasing performance without any good reason, 71, 72 EPO should be explored and exploited for 'brain doping' in ill patients where it may truly have beneficial effects. research grants from Lundbeck and Orthobiotech, as well as by private donations.
